Learn about CUROSURF® (poractant alfa) Intratracheal Suspension. Find clinical data, treatment strategies, pharmacy, administration, and safety considerations. For US Healthcare …

CUROSURF ® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung …

CUROSURF ® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung …

CUROSURF ® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung …

of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and …

CUROSURF delivers more surfactant with less volume, which may improve tolerability and has the potential to reduce complications such as airway obstruction. 9 Clinical studies have not …

CUROSURF ® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung …

CUROSURF ® (poractant alfa) Intratracheal Suspension is available in sterile, ready-to-use rubber-stoppered clear glass vials containing 1.5 mL [120 mg surfactant (extract)] or 3.0 mL …

CUROSURF ® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung …

CUROSURF ® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung …